Search Result

Results for "

HDAC1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Akt (1) Apoptosis (59) Autophagy (19) Bcl-2 Family (1) Beta-lactamase (1) c-Met/HGFR (2) Caspase (2) CDK (5) DNA Methyltransferase (1) Endogenous Metabolite (10) Epigenetic Reader Domain (2) FGFR (1) Filovirus (2) FLT3 (1) Guanylate Cyclase (1) HDAC (166) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (3) Histone Methyltransferase (1) HIV (13) HPV (2) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (5) JAK (2) MDM-2/p53 (1) Microtubule/Tubulin (5) Mitophagy (13) Monoamine Oxidase (1) mTOR (3) Necroptosis (1) NF-κB (1) Notch (10) Organoid (3) Parasite (5) PARP (2) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (5) Pim (1) Proteasome (1) Reactive Oxygen Species (3) SHP2 (1) Topoisomerase (2) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (144) Cardiovascular Disease (1) Infection (14) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (13)
Click Chemistry:	Alkynes (1)

169

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112147

IDO1 and HDAC1 Inhibitor	Indoleamine 2,3-Dioxygenase (IDO) HDAC	Cancer
IDO1 and HDAC1 Inhibitor (Compound 10) is a dual IDO1 and *HDAC1* inhibitor with IC₅₀s of 69.0 nM and 66.5 nM, respectively .

HY-161464

Chlopynostat	HDAC Apoptosis	Cancer
Chlopynostat (Compound 6c) is a *HDAC1* inhibitor with a IC₅₀ value of 67 nM. Chlopynostat reverses STAT4/p66Shc defects by inhibiting HDAC1-induced < b>Apoptosis .

HY-163090

HR488B	HDAC Reactive Oxygen Species Apoptosis	Cancer
HR488B is an efficient *HDAC1* inhibitor. HR488B specifically suppressed the growth of CRC cells by inducing cell cycle G0/G1 arrest and apoptosis. HR488B causes mitochondrial dysfunction, reactive oxygen species (ROS) generation, and DNA damage accumulation .

HY-144297

HDAC1-IN-3	HDAC Parasite	Infection
HDAC1-IN-3 is a potent Pf HDAC1 inhibitor. HDAC1-IN-3 shows antimalarial activity in wild-type and multidrug-resistant parasite strains. HDAC1-IN-3 shows a significant in vivo killing effect against all life cycles of parasites .

HY-151153

HDAC1-IN-5	HDAC Microtubule/Tubulin Caspase Apoptosis	Cancer
HDAC1-IN-5 is a potent *HDAC1* inhibitor with IC₅₀ values of 15 nM and 20 nM for HDAC1 and HDAC6, respectively. HDAC1-IN-5 can enhance the acetylation of histone H3 and α-tubulin, as well as promote the activation of caspase 3 in cancer cells, thereby inducing apoptosis. HDAC1-IN-5 induces chromatin damage by binding with DNA. HDAC1-IN-5 has strong inhibitory activity against tumor growth in xenograft mice .

HY-162361

HDAC1-IN-7

HDAC Cancer

HDAC1-IN-7 (compound 9) is potent HDAC1 inhibitor, with the IC₅₀ of 0.957 mM .
HY-157481

HDAC1-IN-6

HDAC Cancer

HDAC1-IN-6 (compound 1) is an inhibitor of HDAC1 and 11, with an IC₅₀ of 1.9 μM and 1.6 μM, respectively. HDAC1-IN-6 induces differentiation in AML cells .

HDAC1-IN-7	HDAC	Cancer
HDAC1-IN-7 (compound 9) is potent *HDAC1* inhibitor, with the IC₅₀ of 0.957 mM .

HDAC1-IN-6	HDAC	Cancer
HDAC1-IN-6 (compound 1) is an inhibitor of *HDAC1* and 11, with an IC₅₀ of 1.9 μM and 1.6 μM, respectively. HDAC1-IN-6 induces differentiation in AML cells .

HY-145845

HDAC1/MAO-B-IN-1	HDAC Monoamine Oxidase	Neurological Disease
HDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier *HDAC1/MAO-B* inhibitor with IC₅₀ values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease .

HY-149718

Antitumor agent-123	JAK HDAC	Cancer
Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, *HDAC1* and *HDAC6, with IC₅₀* values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. Antitumor agent-123 exhibits moderate activity in solid tumor models .

HY-144298

HDAC1-IN-4

Parasite HDAC Infection

HDAC1-IN-4 (JX34) is a potent Plasmodium falciparum HDAC1 inhibitor shows antimalarial activity (IC₅₀ < 5 nM) and lower cytotoxicity .
HY-139650

HDAC1/2-IN-3

HDAC Cancer

HDAC1/2-IN-3 is a HDAC1 and HDAC2 inhibitor with IC₅₀ values 0-5 and 5-10 nM, respectively.

HDAC1-IN-4	Parasite HDAC	Infection
HDAC1-IN-4 (JX34) is a potent **Plasmodium falciparum HDAC1** inhibitor shows antimalarial activity (IC₅₀ < 5 nM) and lower cytotoxicity .

HDAC1/2-IN-3	HDAC	Cancer
HDAC1/2-IN-3 is a **HDAC1 and HDAC2** inhibitor with IC₅₀ values 0-5 and 5-10 nM, respectively.

HY-N11692

9-Hydroxyoctadecanoic acid 9-Hydroxystearic acid; 9-HSA	HDAC	Cancer
9-Hydroxyoctadecanoic acid (9-HSA) is an *HDAC1* inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM. 9-Hydroxyoctadecanoic acid shows anticancer activity .

HY-156444

HDAC1/CDK7-IN-1	HDAC CDK Apoptosis	Cancer
HDAC1/CDK7-IN-1 (compound 8e) is a dual CDK7 and *HDAC1* inhibitor with IC₅₀s of 893 nM and 248 nM, respectively. HDAC1/CDK7-IN-1 inhibits the growth cells of MDA-MB-231, MCF-7, A549, and HCT-116 cancer cells. HDAC1/CDK7-IN-1 induces cell cycle arrest and apoptosis in HCT-116 cells, as well as hindered the migration of HCT-116 cells .

HY-149946

HDAC-IN-57	HDAC Apoptosis Histone Demethylase
HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC₅₀s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC₅₀ of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity .

HY-16425

RG2833 5 Publications Verification RGFP109	HDAC	Cancer
RG2833 is a brain-penetrant *HDAC* inhibitor with IC₅₀s of 60 nM and 50 nM for HDAC1 and HDAC3, respectively. The K_i values for HDAC1 and HDAC3 are 32 and 5 nM, respectively .

HY-144725

HDAC1/6-IN-1	HDAC Apoptosis	Cancer
HDAC1/6-IN-1 (compound D7) is a potent multitarget inhibitor of GLP, *HDAC6* and *HDAC1, with IC₅₀* values of 1.3, 13, and 89 nM, respectively. HDAC1/6-IN-1 can inhibit the methylation and deacetylation of H3K9 on protein level. HDAC1/6-IN-1 induces cancer cell apoptosis, G0/G1 cell cycle arrest, and blocks migration and invasion .

HY-143497

HDAC1/2 and CDK2-IN-1	HDAC CDK Apoptosis	Cancer
HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent *HDAC1, HDAC2* and CDK2 dual inhibitor, with IC₅₀ values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .

HY-149630

VEGFR2/HDAC1-IN-1	VEGFR HDAC Apoptosis	Cancer
VEGFR2/HDAC1-IN-1 (compound 13) is a potent *VEGFR-2/HDAC* dual inhibitor, with IC₅₀s of 57.83 nM and 9.82 nM, respectively. VEGFR2/HDAC1-IN-1 arrests the cell cycle at the S and G2 phases, and induces apoptosis in HeLa cells. VEGFR2/HDAC1-IN-1 exhibits anti-angiogenic effect .

HY-117583

cis-BG47	HDAC Histone Methyltransferase	Neurological Disease
cis-BG47 is an cis-isomer of BG47, BG47 is a prototypical histone deacetylases *HDAC1* and *HDAC2* selective, optoepigenetic probe. BG47 can bind to and competitively inhibits the deacetylase activity of *HDAC* targets upon a light-induced trans-to-cis isomerization, and increases Histone Methyltransferase H3K9 acetylation. cis-BG47 can be used for neurological disease research .

HY-104008

ACY-957 1 Publications Verification	HDAC	Others
ACY-957 is an orally active and selective inhibitor of *HDAC1* and *HDAC2, with IC₅₀s of 7 nM, 18 nM, and 1300 nM against HDAC1/2/3, respectively, and shows no inhibition on HDAC*4/5/6/7/8/9 .

HY-14842B

Givinostat hydrochloride monohydrate 5+ Cited Publications ITF-2357 hydrochloride monohydrate	HDAC	Cancer
Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively.

HY-14842

Givinostat

5+ Cited Publications

ITF-2357
HDAC Cancer

Givinostat (ITF-2357) is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively.

Givinostat 5+ Cited Publications ITF-2357	HDAC	Cancer
Givinostat (ITF-2357) is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively.

HY-13606

Dacinostat 3 Publications Verification NVP-LAQ824; LAQ824	HDAC Autophagy	Cancer
Dacinostat is a potent *HDAC* inhibitor, with an IC₅₀ of 32 nM; Dacinostat also inhibits *HDAC1* with an IC₅₀ of 9 nM, and used in cancer research.

HY-14842A

Givinostat hydrochloride

ITF-2357 hydrochloride
HDAC Cancer

Givinostat (ITF-2357) hydrochloride is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively .

Givinostat hydrochloride ITF-2357 hydrochloride	HDAC	Cancer
Givinostat (ITF-2357) hydrochloride is a *HDAC* inhibitor with an IC₅₀ of 198 and 157 nM for *HDAC1* and *HDAC3*, respectively .

HY-100719

BRD-6929	HDAC HIV	Infection Cardiovascular Disease
BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase *HDAC1* and *HDAC2* inhibitor with IC₅₀ of 1 nM and 8 nM, respectively. BRD-6929 shows high-affinity to HDAC1 and HDAC2 with K_i of 0.2 and 1.5 nM, respectively. BRD-6929 can be used for mood-related behavioral model research .

HY-153358

TNG260	HDAC	Cancer
TNG260 is a CoREST-selective deacetylase (CoreDAC) inhibitor. TNG260 inhibits *HDAC1* with 10-fold selectivity over *HDAC3. TNG260 leads to HDAC1* inhibition, reverses anti-PD1 resistance driven by loss of STK11. TNG260 decreases intratumoral infiltration of neutrophils. TNG260 exhibits immune-mediated cell killing .

HY-102083

BRD4884

HDAC Neurological Disease

BRD4884 is a potent HDAC inhibitor with IC₅₀ values of 29 nM, 62 nM, and 1.09 µM for HDAC1, 2, and 3, respectively .

BRD4884	HDAC	Neurological Disease
BRD4884 is a potent *HDAC* inhibitor with IC₅₀ values of 29 nM, 62 nM, and 1.09 µM for HDAC1, 2, and 3, respectively .

HY-10221

Vorinostat 85+ Cited Publications SAHA; Suberoylanilide hydroxamic acid	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Infection Cancer
Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), *HDAC6* and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .

HY-12163

Entinostat 35+ Cited Publications MS-275; SNDX-275	HDAC Autophagy Apoptosis	Cancer
Entinostat is an oral and selective class I *HDAC* inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for *HDAC1, HDAC2, and HDAC3*, respectively.

HY-13216

Pyroxamide 4 Publications Verification	HDAC Apoptosis	Cancer
Pyroxamide is a potent inhibitor of histone deacetylase 1 (HDAC1) with an ID₅₀ of 100 nM. Pyroxamide can induce apoptosis and cell cycle arrest in leukemia .

HY-111048

Corin 1 Publications Verification	Histone Demethylase HDAC	Cancer
Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase *(HDAC), with a K_i(inact)* of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.

HY-153358A

(S)-TNG260	HDAC	Cancer
(S)-TNG260 is an isomer of TNG260 (HY-153358). TNG260 is a CoREST selective deacetylase (CoreDAC) inhibitor. TNG260 inhibits HDAC1 with 10-fold selectivity over HDAC3. TNG260 causes HDAC1 inhibition and reverses anti-PD1 resistance driven by STK11 deletion. TNG260 reduces intratumoral infiltration of neutrophils. TNG260 exhibits immune-mediated cell killing.

HY-130493

HPB

HDAC6 Inhibitor HPB
HDAC Cancer

HPB (HDAC6 inhibitor HPB) is a selective HDAC6 inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .

HPB HDAC6 Inhibitor HPB	HDAC	Cancer
HPB (HDAC6 inhibitor HPB) is a selective *HDAC6* inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .

HY-155328

GK444	HDAC	Inflammation/Immunology
GK444 (Compound 15a) is a *HDAC1/2* inhibitor (IC₅₀: 100 and 92 nM for HDAC1/2 respectively). GK444 inhibits Caco-2 cells with IC₅₀ of 4.1 μM. GK444 also reduces TGF-β1 induced COL1A1 mRNA levels in primary normal human lung fibroblasts. GK444 inhibits Bleomycin (HY-108345)-induced lung fibrosis in mice .

HY-115412

Vorinostat-d5 SAHA-d5; Suberoylanilide hydroxamic acid-d5	HDAC Autophagy Mitophagy Filovirus Apoptosis HPV	Infection Cancer
Vorinostat-d5 (SAHA-d5) is the deuterium labeled Vorinostat. Vorinostat (SAHA) is a potent and orally active pan-inhibitor of *HDAC1, HDAC2* and HDAC3 (Class I), HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification .

HY-101780

Tinostamustine 3 Publications Verification EDO-S101; NL-101	HDAC	Cancer
Tinostamustine (EDO-S101) is a pan *HDAC* inhibitor; inhibits *HDAC6, HDAC1, HDAC2* and *HDAC3* with IC₅₀ values of 6 nM, 9 nM, 9 nM and 25 nM, respectively .

HY-13592

HDAC-IN-7 Chidamide impurity	HDAC	Cancer
HDAC-IN-7 (Chidamide impurity) is an impurity of Chidamide. Chidamide is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor.

HY-124053

BRD2492	HDAC	Cancer
BRD2492 (compound 6d) is a potent, selective *HDAC1* and *HDAC2* inhibitor with IC₅₀s of 13.2 nM and 77.2 nM, respecrtively. BRD2492 exhibits >100-fold selectivity for HDAC1/2 over selectivity over HDAC3 and HDAC6. BRD2492 inhibits breast cancer cell lines growth with IC₅₀s of 1.01 μM and 11.13 μM for T-47D and MCF-7 cells, respectively .

HY-149284

JAK/HDAC-IN-3

JAK HDAC Cancer

JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .

JAK/HDAC-IN-3	JAK HDAC	Cancer
JAK/HDAC-IN-3 (13a) is a dual JAK and *HDAC* inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .

HY-N0141

Parthenolide 20+ Cited Publications (-)-Parthenolide	NF-κB Autophagy Mitophagy Apoptosis	Cancer
Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits *HDAC1* protein without affecting other class I/II HDACs.

HY-16026

Ricolinostat 25+ Cited Publications ACY-1215; Rocilinostat	HDAC Apoptosis	Cancer
Ricolinostat (ACY-1215) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits *HDAC1, HDAC2, and HDAC3* with IC₅₀s of 58, 48, and 51 nM, respectively.

HY-13428

Tubacin 10+ Cited Publications	Beta-lactamase HDAC Virus Protease	Cancer
Tubacin is a potent and selective inhibitor of *HDAC6, with an IC₅₀* value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-14718A

Resminostat hydrochloride 2 Publications Verification RAS2410 hydrochloride; 4SC-201 hydrochloride	HDAC	Cancer
Resminostat hydrochloride is a potent inhibitor of *HDAC1, HDAC3* and *HDAC6, with mean IC₅₀* values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-19327

ACY-738 2 Publications Verification	HDAC	Cancer
ACY-738 is a potent, selective and orally-bioavailable *HDAC6* inhibitor, with an IC₅₀ of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC₅₀s of 94, 128, and 218 nM.

HY-W014004

m-Carboxycinnamic acid bishydroxamide CBHA	HDAC	Cancer
m-Carboxycinnamic acid bishydroxamide is a potent *HDAC* inhibitor, exhibiting ID₅₀ values of 10 and 70 nM in vitro for HDAC1 and HDAC3, respectively . m-Carboxycinnamic acid bishydroxamide also induces apoptosis and suppresses tumor growth .

HY-10990

Abexinostat 5 Publications Verification CRA 024781; PCI-24781	HDAC	Cancer
Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with K_i of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM .

HY-151896

HDAC6-IN-14

HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HY-155329

GK718	HDAC	Inflammation/Immunology
GK718 is a *HDAC1/3* inhibitor (IC₅₀: 259 and 139 nM respectively). GK718 increased acetylated histone H3 level in cells. GK718 inhibits Bleomycin (HY-108345) induced pulmonary fibrosis in mice .

HY-112908

RTS-V5

HDAC Proteasome Cancer

RTS-V5 is a dual HDAC/proteasome inhibitor with IC₅₀s of 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively.
HY-111818

TH34

HDAC Cancer

TH34, an HDAC6/8/10 inhibitor with IC₅₀s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11692

9-Hydroxyoctadecanoic acid 9-Hydroxystearic acid; 9-HSA	Apocynaceae Structural Classification Strophanthus sarmentosus DC. Ketones, Aldehydes, Acids Source classification Plants	HDAC
9-Hydroxyoctadecanoic acid (9-HSA) is an *HDAC1* inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM. 9-Hydroxyoctadecanoic acid shows anticancer activity .

HY-N0141

Parthenolide 20+ Cited Publications (-)-Parthenolide	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Euchresta formosana (Hayata) Ohwi Disease Research Fields Cancer	NF-κB Autophagy Mitophagy Apoptosis
Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits *HDAC1* protein without affecting other class I/II HDACs.

HY-10585A

Valproic acid sodium 30+ Cited Publications Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585

Valproic acid 30+ Cited Publications Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-15144

Trichostatin A Maximum Cited Publications 108 Publications Verification TSA	Structural Classification Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC .

Cat. No.	Product Name	Chemical Structure

HY-12163S

Entinostat-d4
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks